The effects of non-steroidal anti-inflammatory compounds on human myometrial contractility

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 109, Issue 1, 2003, Pages 33-40

  Sawdy, Robert J ^a   Sullivan, Mark H F ^a   Bennett, Phillip R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cyclo oxygenase 2; Myometrium; NSAID; Prostaglandins

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CHEMICAL COMPOUND; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; SC 58560; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INCUBATION TIME; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; UTERUS CONTRACTILITY;

EID: 0038347342     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(02)00481-5     Document Type: Article

References (24)

1. Wikland M., Lindblom B., Wilhelmsson L., Wiqvist N. Oxytocin, prostaglandins, and contractility of the human uterus at term. Acta Obstet. Gynecol. Scand. 61:1982;467-472.
2. Wikland M., Lindblom B., Hammarstrom S., Wiqvist N. The effect of prostaglandin I on the contractility of the term pregnant human myometrium. Prostaglandins. 26:1983;905-916.
3. Senior J., Marshall K., Sangha R., Clayton J.K. In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br. J. Pharmacol. 108:1993;501-516.
4. Romero R., Baumann P., Gonzalez R., Gomez R., Rittenhouse L., Behnke E.et al. Amniotic fluid prostanoid concentrations increase early during the course of spontaneous labour at term. Am. J. Obstet. Gynecol. 171:1994;1613-1620.
5. Slater D.M., Dennes W.J., Campa J.S., Poston L., Bennett P.R. Expression of cyclo-oxygenase types-1 and -2 in human myometrium throughout pregnancy. Mol. Hum. Reprod. 5:1999;880-884.
6. Brown N.L., Alvi S.A., Elder M.G., Bennett P.R., Sullivan M.H.F. A spontaneous induction of fetal membrane prostaglandin production precedes clinical labour. J. Endocrinol. 157:1998;R1-R6.
7. Garrioch D.B. The effect of indomethacin on spontaneous activity in the isolated human myometrium and on the response to oxytocin and prostaglandin. Br. J. Obstet. Gynaecol. 85:1978;47-52.
8. Quaas L., Goppinger A., Zahradnik H.P. The effect of acetylsalicylic acid and indomethacin on the catecholamine- and oxytocin-induced contractility and prostaglandin (6-keto-PGF1 alpha, PGF2 alpha) production of human pregnant myometrial strips. Prostaglandins. 34:1987;257-269.
9. Sawdy R.J., Knock G., Bennett P.R., Poston L., Aaranson P. The effect of nimesulide and indomethacin in contractility and calcium current in myometrial smooth muscle from pregnant women. Br. J. Pharmacol. 125:1998;1212-1217.
10. Slattery S.M., Friel A.M., Healy D.G., Morrison J.J. Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro. Obstet. Gynecol. 98:2001;563-569.
11. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S.et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC 58635, celecoxib). J. Med. Chem. 40:1997;1347-1365.
12. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13313-13318.
13. Riendeau D., Percival M.D., Boyce S., Brideau C., Charleson S., Cromlish W.et al. Biochemical and pharmacological profile of a tetra-substituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121:1997;105-117.
14. Noble S., Balfour J.A. Meloxicam. Drugs. 51:1996;424-430.
15. Warner T.D., Guilliano F., Vojnovic I., Bukusa A., Mitchell J.A., Vane J.R. Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7563-7568.
16. Pieber D., Allport V.C., Hills F., Johnson M., Bennett P.R. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol. Hum. Reprod. 7:2001;875-879.
17. Sawdy R.J., Slater D.M., Dennes W.J., Sullivan M.H., Bennett P.R. The roles of the cyclo-oxygenases types one and two in prostaglandin synthesis in human fetal membranes at term. Placenta. 21:2000;54-57.
18. Yousif M.H., Thulesius O. Tocolytic effect of the cyclooxygenase-2 inhibitor, meloxicam: studies on uterine contractions in the rat. J. Pharm. Pharmacol. 50:1998;681-685.
19. Griffin B.W., Magnino P.E., Pang I.H., Sharif N.A. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J. Pharmacol. Exp. Ther. 286:1998;411-418.
20. Willoughby D.A., Moore A.R., Colville-Nash P.R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 355:2000;646-648.
21. Turck D., Busch U., Heinzel G., Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimitt. 47:1997;253-258.
22. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin. Pharmacokinet. 35:1998;247-274.
23. Helleberg L. Clinical pharmacokinetics of indomethacin. Clin. Pharmacokinet. 6:1981;245-258.
24. Souter D., Harding J., McCowan L., O'Donnell C., McLeay E., Baxendale H. Antenatal indomethacin - adverse fetal effects confirmed. Aust. N. Z. J. Obstet. Gynaecol. 38:1998;11-16.